The FDA has authorized the emergency use of Chembio Diagnostics’ (CEMI +3.2%) point-of-care DPP COVID-19 System for the rapid detection of IgM and IgG antibodies to SARS-CoV-2 from a fingerstick sample.
The company launched the product earlier this month which the FDA is allowing during the pandemic for properly validated tests.
https://seekingalpha.com/news/3560877-fda-oks-emergency-use-of-chembio-rapid-blood-test-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.